Measure binding of small molecule drug candidates to target protein in a cellular environment with Alpha SureFire® CETSA® target engagement assays. For use in combination with Pelago Bioscience's CETSA® (Cellular Thermal Shift Assay) technology, this kit provides a convenient no-wash assay for detection and quantitation of small molecule binding to p38 MAPK, and can be used in hit identification, hit confirmation, and lead optimization studies for increased confidence and better prediction early in the drug discovery process. Please note that a valid CETSA® subscription from Pelago Biosciences is required for use.
For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Alpha SureFire® CETSA® Target Engagement kits efficiently assess target engagement in live cells, on endogenously expressed target protein with no need for engineered protein constructs or cell lines to gain confidence with earlier, better prediction in the drug discovery process.
The Cellular Thermal Shift Assay (CETSA®) assesses the thermal stability of proteins in living cells and cell lysate based on denaturation and aggregation upon heating. The relative amount of remaining soluble protein after heating is measured, and a thermal melting curve of target protein is generated. Compound binding affects the thermal stability of the protein, with a shift in the melting curve indicative of cellular target engagement.
CETSA® is performed by incubating intact cells with the test compound. A melting curve is generated where the sample, in the presence and in the absence of a reference compound, is heat challenged at 12 different temperatures. From the melting curve, a single temperature is selected where there is an obvious shift of the reference compound. This single temperature is then used to perform single concentration or concentration-response curve compound screening. An alternative assay format is to run the assay with disrupted cells. This is useful in measuring the ability of the compound to engage the target protein independently of its ability to cross the cell membrane, and of its potential efflux or metabolization by the cells.Alpha SureFire® CETSA® assay kits enable the rapid, sensitive, and quantitative detection of target protein that remains soluble after heat treatment of compound-treated cells without any need for separating soluble and aggregated protein (no washing steps; no separation steps). In an Alpha SureFire® CETSA® assay, one antibody against target protein binds to streptavidin-coated Alpha Donor beads, while a second antibody against the target is bound through a proprietary CaptSure™ agent to AlphaLISA Acceptor beads. In the presence of the target protein, the two antibodies bring the Donor and Acceptor Beads close to each other, enabling the generation of an Alpha signal upon illumination of Donor Beads by the Alpha-enabled plate reader, such as the EnVision®, EnSight™, or VICTOR Nivo multimode plate readers. The amount of light emission is directly proportional to the amount of soluble protein present in the sample.
This assay eliminates the need for laborious techniques, such as Western blotting or conventional ELISA. Alpha SureFire® CETSA® is a homogeneous assay with no sample washing steps required, allowing for minimal handling, short assay times, better well-to-well reproducibility (lower CV%), and robotic operation if desired.
|Assay Target||p38 MAPK|
|Assay Target Class||Protein|
|Product Brand Name||Alpha SureFire CETSA|
|Unit Size||500 assay points|
Product brochure for the Alpha Technology, a versatile, no wash, homogeneous assay technology that's suitable for a broad range of applications.
Find out about our range of integrated solutions for drug discovery screening in this e-brochure.
Our screening solutions for high-throughput screening, phenotypic screening and data analysis help to streamline drug discovery workflows in labs across the globe. Our portfolio includes automated liquid handling, assays and reagents, imaging and detection systems, and informatics.
Working independently or together, with our solutions you can achieve consistent and accurate results. By accelerating the identification and characterization of effective and safe drug candidates, the PerkinElmer portfolio enables you to optimize efficiency in your lab and deliver more actionable, real-world results.
Download the brochure to learn more about how we can partner with you so that you can discover smarter, more effective, data-driven breakthroughs in the critical screening stages of drug discovery and development.